logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme's Gaucher Drug Shows Positive Results In Follow Up Data Of Phase 2 Trial

Genzyme Corp., a unit of Sanofi-Aventis (SNY,SNYNF.PK), Wednesday said that a four-year follow-up data from a phase 2 trial for its investigational oral drug 'eliglustat tartrate' for Gaucher disease, showed further improvements across all endpoints.

Sustained or further improvements were observed across all endpoints, including markers of bone disease, at the four-year timepoint, Genzyme said in a statement.

Gaucher disease (pronounced Go-shay) is an inherited genetic disorder, in which patients lack the normal form of glucocerebrosidase, or GCD enzyme that breaks down specific fat molecules. The lack of this enzyme results in the accumulation of fat in liver, spleen and bone marrow. The disease affects about 1 in 100,000 persons in the general population.

Genzyme previously reported that the 52-week phase 2 trial of eliglustat tartrate had met its primary composite endpoint. Patients have continued to receive eliglustat tartrate in the extension portion of the study for over four years. The data from patients on eliglustat tartrate after four years indicate continued or stabilized improvements across all endpoints.

The composite endpoint is clinically meaningful response in at least two of three endpoints i.e. improvements in spleen size, hemoglobin and platelet levels in individual patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of thyssenKrupp AG were gaining around 2 percent in the morning trading in Germany after the steel giant Thursday said it expects clearly positive net income and significantly higher adjusted EBIT, a key earnings metric, in fiscal 2018. This was after reporting higher adjusted EBIT, sales and order intake in its fiscal 2017, despite a net loss due to charges. Senator Lisa Murkowski, R-Alaska, has expressed support for repealing Obamacare's individual mandate, a key provision Senate Republicans are hoping to use to offset the cost of their tax reform bill. The Congressional Budget Office estimates repealing the requirement that nearly all Americans purchase... Automotive startup Divergent 3D said that a Chinese-led investment syndicate has agreed to commit up to $107 million in financing through a new investment round. Hong Kong-based investment holding company, O Luxe Holdings Limited, led the investment group, which includes Horizons Ventures, Shanghai Alliance Investment Limited and Altran Technologies.
comments powered by Disqus
Follow RTT